Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice

File Description SizeFormat 
Eurogin 2015 Roadmap SF screening060616-clean.docFile embargoed until 11 January 2018443.5 kBMicrosoft Word    Request a copy
Eurogin Roadmap SF Tables-060616-2.docFile embargoed until 11 January 201850.5 kBMicrosoft Word    Request a copy
Title: Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice
Author(s): Wentzensen, N
Arbyn, M
Berkhof, J
Bower, M
Canfell, K
Einstein, M
Farley, C
Monsonego, J
Franceschi, S
Item Type: Journal Article
Abstract: Human papillomaviruses (HPVs) are the necessary cause of most cervical cancers, a large proportion of other anogenital cancers, and a subset of oropharyngeal cancers. The knowledge about HPV has led to development of novel HPV-based prevention strategies with important impact on clinical and public health practice. Two complementary reviews have been prepared following the 2015 Eurogin Conference to evaluate how knowledge about HPV is changing practice in HPV infection and disease control through vaccination and screening. This review focuses on screening for cervical and anal cancers in increasingly vaccinated populations. The introduction of HPV vaccines a decade ago has led to reductions in HPV infections and early cancer precursors in countries with wide vaccination coverage. Despite the high efficacy of HPV vaccines, cervical cancer screening will remain important for many decades. Many healthcare systems are considering switching to primary HPV screening, which has higher sensitivity for cervical precancers and allows extending screening intervals. We describe different approaches to implementing HPV-based screening efforts in different healthcare systems with a focus in high-income countries. While the population prevalence for other anogenital cancers is too low for population-based screening, anal cancer incidence is very high in HIV-infected men who have sex with men, warranting consideration of early detection approaches. We summarize the current evidence on HPV-based prevention of anal cancers and highlight important evidence gaps.
Publication Date: 11-Jan-2017
Date of Acceptance: 8-Dec-2016
URI: http://hdl.handle.net/10044/1/49097
DOI: https://dx.doi.org/10.1002/ijc.30579
ISSN: 1097-0215
Publisher: Wiley
Start Page: 2192
End Page: 2200
Journal / Book Title: International Journal of Cancer
Volume: 140
Issue: 10
Copyright Statement: © 2016 UICC. This is the accepted version of the following article, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1002/ijc.30579/abstract
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
HPV
screening
cervical cancer
anal cancer
cytology
vaccination
CERVICAL INTRAEPITHELIAL NEOPLASIA
HUMAN-PAPILLOMAVIRUS INFECTION
RANDOMIZED CONTROLLED-TRIAL
ANAL CANCER PRECURSORS
DUAL-STAINED CYTOLOGY
SELF-SAMPLING KITS
HIV-POSITIVE MEN
NATURAL-HISTORY
HOMOSEXUAL-MEN
HUMAN IMMUNODEFICIENCY
HPV
anal cancer
cervical cancer
cytology
screening
vaccination
Female
Humans
Male
Neoplasms
Papillomaviridae
Papillomavirus Infections
Papillomavirus Vaccines
Vaccination
Science & Technology
Life Sciences & Biomedicine
Oncology
HPV
screening
cervical cancer
anal cancer
cytology
vaccination
CERVICAL INTRAEPITHELIAL NEOPLASIA
HUMAN-PAPILLOMAVIRUS INFECTION
RANDOMIZED CONTROLLED-TRIAL
ANAL CANCER PRECURSORS
DUAL-STAINED CYTOLOGY
SELF-SAMPLING KITS
HIV-POSITIVE MEN
NATURAL-HISTORY
HOMOSEXUAL-MEN
HUMAN IMMUNODEFICIENCY
Oncology & Carcinogenesis
1112 Oncology And Carcinogenesis
Publication Status: Published
Embargo Date: 2018-01-11
Appears in Collections:Division of Surgery
Division of Cancer
Faculty of Medicine



Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons